← Eichor
Study identifier: NCT04974346 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Para-aortic Prophylactic Irradiation for Locally Advanced Cervical Cancer

Condition: Cervical Cancer  ·  Sponsor: Zhejiang Cancer Hospital

PhasePhase 3
Planned participants455
Who can joinFemale, 18 Years to 75 Years
Healthy volunteersNo

About this study

Para-aortic lymph node metastasis is a poor prognostic factor for locally advanced cervical cancer, but false negative diagnosis is easy to occur. The aim of this trial was to investigate whether para-aortic prophylactic radiotherapy improves disease-free survival in patients with positive pelvic lymph nodes below the common iliac artery.

This description comes directly from the study's public registry record.

Talk to the study team

Xiang Zhang  ·  0086-571-88122148  ·  zhangxiang@zjcc.org.cn

Always discuss trial participation with your own doctor first.

Locations (7)

Zhejiang Cancer HospitalHangzhou, Zhejiang, ChinaRecruiting
The First Affiliated Hospital, Zhejiang University School of MedicineHangzhou, ChinaActive Not Recruiting
Jinhua Municipal Central Hospital Medical GroupJinhua, ChinaActive Not Recruiting
Lishui People's HospitalLishui, ChinaActive Not Recruiting
Ningbo First HospitalNingbo, ChinaActive Not Recruiting
Taizhou Central HospiatlTaizhou, ChinaActive Not Recruiting
Chongqing University Three Gorges HospitalWanzhou, ChinaActive Not Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04974346